Haleon rejects Zantac indemnification requests from GSK, Pfizer, Health Information, ET HealthWorld

London: Haleon on Tuesday mentioned it had notified GSK and Pfizer that it had rejected their requests for indemnification on the subject of U.S.-based litigation over the heartburn drug, Zantac.

Greater than 2,000 criminal instances associated with Zantac had been filed in america over allegations that the compound comprises possible cancer causing agents.

Zantac, at the start advertised by means of a forerunner of GSK, has been bought by means of a number of firms at other instances, together with Pfizer, Boehringer Ingelheim and Sanofi in addition to a plethora of generic drugmakers.

Haleon, spun out as an impartial corporate in July, incorporates shopper well being property as soon as owned by means of GSK and Pfizer.

Practice and connect to us on , Facebook, Linkedin, Youtube

Source link

Posted on

Leave a Reply

Your email address will not be published.